(HealthDay News) — For patients with allergic asthma, a novel DNA enzyme that is able to cleave and inactivate GATA3 mRNA, SB010, attenuates early and late asthmatic responses, according to a study published online May 17 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Thoracic Society, held from May 15–20 in Denver.
Norbert Krug, MD, from Hannover Medical School in Germany, and colleagues conducted a randomized trial involving patients with allergic asthma with sputum eosinophilia and who had biphasic early and late asthmatic responses after laboratory-based allergen provocation. A group of 40 patients were randomized to receive 10mg of SB010 (21 patients) or placebo (19 patients) administered by inhalation once daily for 28 days.
The researchers found that SB010 correlated with a 34% reduction in the mean late asthmatic response, compared with the baseline response, based on the area under the curve for forced expiratory volume in one second (FEV1), while there was a 1% increase in the AUC for FEV1 with placebo (P=0.02). The early asthmatic response was attenuated by 11% with SB010 and increased by 10% with placebo (P=0.03).
“Treatment with SB010 significantly attenuated both late and early asthmatic responses after allergen provocation in patients with allergic asthma,” the authors write.
The study was funded by Sterna Biologicals.